CA2504999A1 - Therapeutic compounds and methods - Google Patents

Therapeutic compounds and methods Download PDF

Info

Publication number
CA2504999A1
CA2504999A1 CA002504999A CA2504999A CA2504999A1 CA 2504999 A1 CA2504999 A1 CA 2504999A1 CA 002504999 A CA002504999 A CA 002504999A CA 2504999 A CA2504999 A CA 2504999A CA 2504999 A1 CA2504999 A1 CA 2504999A1
Authority
CA
Canada
Prior art keywords
optionally substituted
compound
compound according
group
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002504999A
Other languages
English (en)
French (fr)
Inventor
Barbara Martha Meurer-Grimes
Jin Yu
Gino Luigi Vairo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sarawak Government of State of Malaysia
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/291,863 external-priority patent/US6710075B2/en
Application filed by Individual filed Critical Individual
Publication of CA2504999A1 publication Critical patent/CA2504999A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA002504999A 2002-11-08 2003-11-06 Therapeutic compounds and methods Abandoned CA2504999A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/291,863 2002-11-08
US10/291,863 US6710075B2 (en) 2000-07-05 2002-11-08 Therapeutic compounds and methods
PCT/AU2003/001463 WO2004041812A1 (en) 2002-11-08 2003-11-06 Therapeutic compounds and methods

Publications (1)

Publication Number Publication Date
CA2504999A1 true CA2504999A1 (en) 2004-05-21

Family

ID=32312131

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002504999A Abandoned CA2504999A1 (en) 2002-11-08 2003-11-06 Therapeutic compounds and methods

Country Status (5)

Country Link
EP (1) EP1569928A4 (de)
JP (1) JP4847014B2 (de)
AU (1) AU2003277988A1 (de)
CA (1) CA2504999A1 (de)
WO (1) WO2004041812A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101391746B1 (ko) 2011-06-16 2014-05-12 카톨리에케 유니버시타이트 로이벤 케이.유. 로이벤 알 앤 디 인다논 유도체, 이의 약학적으로 허용되는 염 또는 이의 광학 이성질체, 이의 제조방법 및 이를 유효성분으로 함유하는 바이러스성 질환의 예방 또는 치료용 약학적 조성물
KR101630243B1 (ko) 2012-12-14 2016-06-15 한국화학연구원 신규한 화합물, 이의 약학적으로 허용가능한 염 또는 이의 광학 이성질체, 이의 제조방법 및 이를 유효성분으로 함유하는 바이러스성 질환의 예방 또는 치료용 약학적 조성물
US10639378B2 (en) 2016-06-06 2020-05-05 Genentech, Inc. Silvestrol antibody-drug conjugates and methods of use
CN115916763A (zh) 2020-04-20 2023-04-04 诺华股份有限公司 抗病毒素1,3-二氧代茚化合物
CN115385924B (zh) * 2022-10-06 2023-10-13 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) 一种具有抗肿瘤活性的环戊烷苯并呋喃类化合物及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19835325A1 (de) * 1998-08-05 2000-02-10 Bayer Ag Verwendung von Cyclopentabenzofuran-Derivaten zur Bekämpfung von NF-kB abhängigen Krankheiten
AUPQ866500A0 (en) * 2000-07-05 2000-08-03 Exgenix Operations Pty Ltd Therapeutic compounds and methods

Also Published As

Publication number Publication date
JP4847014B2 (ja) 2011-12-28
JP2006508098A (ja) 2006-03-09
EP1569928A4 (de) 2008-12-10
AU2003277988A1 (en) 2004-06-07
WO2004041812A1 (en) 2004-05-21
EP1569928A1 (de) 2005-09-07

Similar Documents

Publication Publication Date Title
Proksch et al. Chemistry and biological activity of rocaglamide derivatives and related compounds in Aglaia species (Meliaceae)
Jim-Min et al. Lignans from leaves of Juniperus chinensis
Morikawa et al. New farnesane-type sesquiterpenes, hedychiols A and B 8, 9-diacetate, and inhibitors of degranulation in RBL-2H3 cells from the rhizome of Hedychium coronarium
Sun et al. Three new cytotoxic aryltetralin lignans from Sinopodophyllum emodi
US6710075B2 (en) Therapeutic compounds and methods
CN107163011B (zh) 3-(3,4,5-三甲氧基苯甲酰)-苯并呋喃类微管蛋白抑制剂及其制备方法和用途
Kofujita et al. A diterpene quinone from the bark of Cryptomeria japonica
CA2983299C (en) Plant-based biologically active substance having a polypharmacological effect
Sugawara et al. Zearalenone derivatives produced by the fungus Drechslera portulacae
CN105153086A (zh) 一种新的倍半萜类化合物及其制备方法和医药用途
CA2504999A1 (en) Therapeutic compounds and methods
Cedrón et al. Chemistry and biology of Pancratium alkaloids
JP2004501983A5 (de)
Peng et al. Biologically active secoiridoids: A comprehensive update
Carotenuto et al. 12-Keto-porrigenin and the unique 2, 3-seco-porrigenin, new antiproliferative sapogenins from Allium porrum
AU2001268848B2 (en) Therapeutic compounds and methods
MIYASE et al. Studies on the Constituents of Hedysarum polybotrys HAND.-MAZZ.
Shi et al. Structurally novel C 17-sesquiterpene lactones from Ainsliaea pertyoides
AU2001268848A1 (en) Therapeutic compounds and methods
JP4769726B2 (ja) コンセントリコリド及びその誘導体、それらを調製する工程、それを含む薬学的組成物並びにその使用
Brahmachari Nevadensin: Isolation, chemistry and bioactivity
Huang et al. Anti-inflammatory secoiridoid glycosides from Gentianella azurea
KR101825614B1 (ko) C-메틸이소플라본과 그 유도체 및 그 합성방법
Pérez et al. Lignans from Apollonias barbujana
KR101457638B1 (ko) 피라졸릴나프탈레놀 유도체, 그 제법 및 그것을 포함하는 항암 조성물

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead